2025 Distinct Roles of OPTN Variants in ALS, FTD and Glaucoma: Insights from Experimental Models and Computational Analyses, 9th Rijeka Forum on Neurodegenerative Diseases, Rijeka, Croatia; invited talk I. Munitic
2025 Of Mice and Men: OPTN Variants in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia, Mind and Brain, Pula, Croatia; invited talk I. Munitic
2025 Optineurin in Neurodegenerative Diseases: True to its Multifunctionality?, seminar at Purdue University, special seminar I. Munitic
2025 The Present and Future of Targeting Immunity in Neurodegenerative Diseases, Alzheimer's Association AAIC Neuroscience Next, Belgrade, Serbia; invited talk I. Munitic
2024 Immune Imbalance during Aging: Lessons from the Mouse Models, UPO Aging Project, University of Eastern Piedmont, Novara, Italy; invited talk I. Munitic
2023 Analysis of OPTN variants in neurodegenerative diseases, 8th Rijeka Forum on
Neurodegenerative Diseases, Rijeka, Croatia; invited talk I. Munitic
2023 Immune Imbalance during Ageing, SiNAPSA Neuroscience Conference '23,
Ljubljana, Slovenia; invited talk I. Munitic
2023 Neuroimmunity in amyotrophic lateral sclerosis – mechanistic potential, 7th Rijeka
forum on neurodegenerative diseases, Rijeka, Croatia; invited talk I. Munitic
2023 Neuroinflammation: A key target or bye-player in neurodegenerative diseases? Controversies in Neurology (CONy), Dubrovnik, Croatia; invited talk I. Munitic
2023 Je li ALS upalna bolest? Dileme u neurologiji, Brač, Croatia; invited talk I. Munitic
2022 Multifaceted role of optineurin in neurodegenerative diseases, 6th Rijeka forum on neurodegenerative diseases, Rijeka, Croatia; invited talk I. Munitic
2022 Immunity in amyotrophic lateral sclerosis: blurred lines between excessive inflammation and inefficient immune responses 10th Croatian Congress of Pharmacology Opatija, Croatia; invited talk I. Munitic
2022 The love-hate relationship between the brain and the immune system, Darwin Regional conference (online) Rijeka, Croatia; invited talk I. Munitic
2021 Mechanistic insights into the pathophysiology of ALS, online congress, Prtenjača N: Regulation of TDP-43 and optineurin
2020 ENCALS, online congress; Prtenjača N: Crosstalk of TDP-43 and optineurin
2020 Glia in Health & Disease, online congress; Prtenjača N: Regulation of TDP-43 and optineurin
2019 HDBMB Crossroads in Life Sciences, Lovran, Croatia; Munitic I: Optineurin Dysfunction in Amyotrophic Lateral Sclerosis
2019 23rd Young Neuroscientist Meeting, Trieste, Italy; Prtenjača N: Elucidating the Role of Optineurin in Inflammation and Autophagy
2019 Mind & Brain, Pula, Croatia; Munitic I: Optineurin Dysfunction in Neurodegeneration
2019 International Conference on Neurological Disorders and Neurorestoration, Dubrovnik, Croatia; Munitic I: Immunity in Amyotrophic Lateral Sclerosis
2019 4th Croatian Neuroimmunological Congress with international participation, Opatija, Croatia; Munitic I: Neuroimmunology of ALS
2019 Diagnostics and Therapy of Motor Neuron Disorders, Zagreb, Croatia; Munitic I: Neurodegeneration and Immunity
2018 Annual Meeting of the Croatian Immunological Society, Zadar, Croatia; Markovinovic A: Loss of optineurin leads to disbalance in pro- and anti-inflammatory factors regulated by IFN-β
2018 XXVII AINI Congress 2018, Trieste, Italy; Markovinovic A: Loss of optineurin leads to disbalance in pro- and anti-inflammatory factors regulated by IFN-β
2018 Dilemmas in neurology, Poreč, Croatia; Munitic I: Immunology in ALS: historic overview and future perspectives
2018 Faculty for Humanities, and Social Sciences, University of Rijeka, Croatia; Munitic I: Vaccination: scientific foundations
2018 Annual meeting of Croatian Laboratory Animal Science Association (CroLASA), Zagreb, Croatia; Munitic I: Developing new mouse models for studying amyotrophic lateral sclerosis
2017 13th Symposium of the André-Delambre Foundation, Montreal, Canada; Munitic I: Characterization of the role of optineurin in neurodegeneration, .
2017 Laval University, CERVO Brain, Research Centre Quebec City, Canada; Munitic I: Elucidating the role of optineurin in amyotrophic lateral sclerosis
2017 Croatian National Academy of Sciences and Arts 1st Rijeka Forum on Neurodegenerative Diseases,
Rijeka, Croatia; Munitic I: Animal Models of Amyotrophic Lateral Sclerosis,
2017 Croatian Science Foundation installation grant presentation, Medical Faculty, University of Rijeka, Croatia; Munitic I: Elucidating the role of optineurin in neuroprotection,
2017 Regional meeting of clinicians and basic scientists that work on ALS, Ljubljana, Slovenia; Munitic I: Molecular characterization of mouse optineurin insufficiency models,
2016 20th Young Neuroscientists Meeting, Rijeka, Croatia; Markovinovic A: An optineurin insufficiency model as a potential tool for elucidating the pathogenesis of amyotrophic lateral sclerosis
2016 Faculty for Humanities, and Social Sciences, University of Rijeka, Croatia; Munitic I: Experiences and challenges of young researchers in biomedicine
2016 European Network for the Cure of ALS (ENCALS) meeting, Milano, Italy: Munitic I: An Optineurin insufficiency model of ALS.
2015 4th European Congress of Immunology, Vienna, Austria; Munitic I: Endogenous Glucocorticoids Suppress Dendritic Cell-derived IL-12 and Prevent Death in LPS-induced sepsis,
2014 10th Symposium of the André-Delambre Foundation, Montreal, Canada; Munitic I: A Mouse Model of Optineurin Insufficiency
2014 Symposium of the Croatian National Academy of Sciences, “New discoveries in immunology and hematology”, Rijeka, Croatia; Munitic I: New functions of dendritic cells: novel DC with T cell attributes (TDC) and DC regulation by glucocorticoids during sepsis.
